fbpx

COVID-19 update, 20 Mar

Drug combination works in hospitalized patients!

A small French study shows that an old malaria drug, hydroxychloroquine (HCQ) combined with (AZ) azithromycin.

The graph below shows the percent of patients with a nasal swab that contains the virus.

Black line (control), no change over six days.

Blue line, HCQ alone, nice reduction that is different from control on day 3 but is not cured by day six.

Green line, HCQ plus AZ together, better reduction than HCQ alone and NO VIRUS by day 5!

Caveat: a 20 patient study so results may differ on a big scale but this is a major breakthrough.

Note: my previous analysis of HCQ based on test tube data was that it would fail. I am glad it was tested!

Here is the paper if you want details.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest

About Dr. Quay

Steven Quay is the CEO of Atossa Therapeutics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for breast cancer and COVID-19. He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. A TEDx talk he delivered on breast cancer prevention has been viewed over 200,000 times. His 300+ contributions to medicine have been cited over 9,900 times, placing him in the top 1% of scientists worldwide. He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have helped over 80 million people.

The COVID-19 HOPE Clinical Trial​